SCHEMBL7652833

SCHEMBL7652833

Cc1nc2ccc(C(=O)NS(=O)(=O)c3ccc(Cl)s3)cc2n1Cc1ccc(-c2ccccc2)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 10/20 0.54
HDAC1 Q13547 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ABCB1 P08183 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
RORC P51449 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7650828 0.92 PPARG (0.53) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL7656766 0.89 PPARG (0.67) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL6307995 0.89 PPARG (0.51) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL7652854 0.88 PPARG (0.56) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL6303321 0.86 PPARG (0.50) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL6135129 0.86 PPARG (0.56) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL6299271 0.86 MAPT (0.41) PPARGALDH1A1MAPTSMN1; SMN2ABCB1
SCHEMBL6308625 0.86 PPARG (0.54) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL6308886 0.83 PPARG (0.61) PPARGHDAC1HDAC6HDAC3HDAC4
SCHEMBL6301164 0.83 PPARG (0.56) PPARGHDAC1HDAC6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP claimed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed